ReNeuron Group plc
("ReNeuron" or "the Group")
Share Purchases by a Director and a PDMR
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces that Barbara Staehelin, Senior Independent Non-Executive Director and Suzanne Hancock, COO and PDMR of the Company, have purchased 100,000 and 42,128 respectively of the Company's ordinary shares of 1p each ("Ordinary Shares").
| Name | Title | Number of Ordinary Shares purchased | Resulting beneficial interest in the Company's Ordinary Shares | Percentage of Company's Total Voting Rights |
| Barbara Staehelin | Senior Independent NED | 100,000 | 270,000 | 0.472% |
| Suzanne Hancock | Chief Operations Officer | 42,128 | 42,128 | 0.074% |
ENDS
Enquiries:
| ReNeuron | ||
| Iain Ross, Chairman | Via Walbrook PR | |
| John Hawkins, Chief Financial Officer | | |
| | | |
| Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking) | +44 (0)20 3100 2000
| |
| | | |
| Allenby Capital Limited (Joint Broker) | +44 (0)20 3328 5656 | |
| James Reeve/George Payne (Corporate Finance) | | |
| Stefano Aquilino (Sales & Corporate Broking) | | |
| | | |
| Walbrook PR (Media & Investor Relations) | +44 (0)20 7933 8780 or reneuron@walbrookpr.com | |
| Paul McManus / Alice Woodings | +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Barbara Staehelin | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Senior Independent non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | ReNeuron Group plc | ||||
| b) | LEI | 2138003TU12CQ5TZO137 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00BF5G6K95 | ||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information | 100,000 ordinary shares at an average price of 10.20p at a total value of £10,200 | ||||
| e) | Date of the transaction | 23 January 2023 | ||||
| f) | Place of the transaction | London Stock Exchange AIM Market | ||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Suzanne Hancock | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Operations Officer/PDMR | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | ReNeuron Group plc | ||||
| b) | LEI | 2138003TU12CQ5TZO137 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 1p RENE - GB00BF5G6K95 | ||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information | 42,128 ordinary shares at an average price of 11.84p at a total value of £4,987.96 | ||||
| e) | Date of the transaction | 30 January 2023 | ||||
| f) | Place of the transaction | London Stock Exchange AIM Market | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.